Clinical trials: Cephalalgia
Migraine Without Aura
Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura
This is a a multi-center, randomized, double-blind, parallel group, and placebo controlled, two-arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache without aura.
- Trial name
- NCT00959751
- Testing
- NXN-188
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- NeurAxon Inc.
Migraine Disorders
Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
A study to assess the safety, tolerability, and single dose pharmacokinetics of a marketed drug in pediatric subjects with migraines.
- Trial name
- NCT00604812
- Testing
- rizatriptan benzoate (5 mg), rizatriptan benzoate (10 mg)
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Dizziness, Nausea
Efficacy of a Transcranial Vibrating System for Mitigation of Migraine Associated Vertigo
Vertigo is among the most common symptoms associated with migraine and affects 26.5% of migraine sufferers, leading to a dramatic impact in life limiting even the most simple activities.
- Conditions
- Dizziness, Nausea, Headache, Confusion
- Trial name
- NCT03886012
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs
Migraine Disorders
MMA Embolization for Refractory Chronic Migraine
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic…
- Trial name
- MIGRAINE (NCT06735833)
- Testing
- Middle Meningeal Artery embolization
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
Migraine With or Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT03061734)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)
The purpose of this study is to investigate the safety and tolerability of telcagepant (MK-0974) in the long-term treatment of acute migraine in adult participants.
- Trial name
- NCT00443209
- Testing
- Telcagepant 300 mg soft gel capsules, Telcagepant 280 mg tablets, Rizatriptan 10 mg tablets
- Volunteers
- 1,068 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study
Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and…
- Trial name
- NCT02901756
- Testing
- Antemig
- Volunteers
- 132 people
- Sponsor
- PiLeJe
High Blood Pressure, Migraine Headaches
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Trial name
- NCT00960245
- Testing
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sandoz
Migraine
The Effect of Nasal Carbon Dioxide in the Treatment of Moderate to Severe Migraine
This multi-center, double-blind, placebo-controlled, parallel group trial carbon dioxide in the treatment of moderate to severe migraine.
- Trial name
- NCT01253915
- Testing
- Nasal Carbon Dioxide
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Capnia, Inc.
Headache, Migraine
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
- Trial name
- NCT02792517
- Testing
- Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive
- Where
- 4 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Amgen
Migraine, Migraine With Aura
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Study STS101-002 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute…
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- EMERGE (NCT03901482)
- Testing
- Dihydroergotamine
- Where
- 117 sites in United States
- Volunteers
- 1,201 people
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Headache Disorders
Occipital Nerve Stimulation to Treat Chronic Headaches
The purpose of this study is to evaluate the safety and efficacy of a implantable device, called the bion(R), in the treatment of chronic headache.
- Trial name
- NCT00205894
- Testing
- bion microstimulator
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Migraine With Aura, Migraine Without Aura
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
- Trial name
- NCT00123201
- Testing
- Dronabinol MDI
- Where
- 29 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
- Trial name
- NCT00797667
- Testing
- Telcagepant 140 mg, Telcagepant 280 mg
- Volunteers
- 660 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
Acute Treatment of Migraine With e-TNS
The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients.
- Trial name
- ACME (NCT02590939)
- Testing
- CEFALY Active
- Where
- 3 sites in United States
- Volunteers
- 106 people
- Sponsor
- Cefaly Technology
Migraine Headache
Ketone for Migraine Prevention
Efficacy of a nutritional ketogenic supplement (NKS) in reducing the number, intensity, and duration of migraine headaches in episodic migraine patients.
- Trial name
- NCT05085483
- Testing
- Nutritional Ketogenic Supplement
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Société des Produits Nestlé (SPN)
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
A migraine is a moderate to severe headache on one side of the head that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- ATO-TOPIRAMATE (NCT05748483)
- Testing
- Atogepant, Topiramate
- Where
- 81 sites in Austria, Belgium and 10 more
- Volunteers
- 545 people
- Sponsor
- AbbVie
Migraine
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
Migraine is a common neurological disorder typically characterized by attacks of throbbing or pulsating headache on one side of the head of moderate to severe pain intensity.
- Trial name
- EMPRESS (NCT05158894)
- Where
- 2 sites in United States, Canada
- Volunteers
- 1,884 people
- Sponsor
- AbbVie